{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(4)"],"submitter":["Pallett SJ"],"funding":["Wellcome Trust","Engineering and Physical Sciences Research Council"],"pubmed_abstract":["IntroductionImmunoassays targeting different SARS-CoV-2-specific antibodies are employed for seroprevalence studies. The degree of variability between immunoassays targeting anti-nucleocapsid (anti-NP; the majority) vs the potentially neutralising anti-spike antibodies (including anti-receptor-binding domain; anti-RBD), particularly in mild or asymptomatic disease, remains unclear.AimsWe aimed to explore variability in anti-NP and anti-RBD antibody detectability following mild symptomatic or asymptomatic SARS-CoV-2 infection and analyse antibody response for correlation with symptomatology.MethodsA multicentre prospective cross-sectional study was undertaken (April-July 2020). Paired serum samples were tested for anti-NP and anti-RBD IgG antibodies and reactivity expressed as binding ratio"],"journal":["Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8796290"],"repository":["biostudies-literature"],"pubmed_title":["Variability in detection of SARS-CoV-2-specific antibody responses following mild infection: a prospective multicentre cross-sectional study, London, United Kingdom, 17 April to 17 July 2020."],"pmcid":["PMC8796290"],"funding_grant_id":["EP/N002474/1","209411/Z/17/Z","EP/M027007/1"],"pubmed_authors":["Denny SJ","Pantelidis P","McClure MO","Patel A","Randell P","Abdulaal A","Rayment M","Moore LS","O'Shea MK","Pallett SJ","Pallett MA","Toumazou C","Rosadas de Oliveira C","Khan M","Jones R","Tedder R","Davies GW","Mughal N"],"additional_accession":[]},"is_claimable":false,"name":"Variability in detection of SARS-CoV-2-specific antibody responses following mild infection: a prospective multicentre cross-sectional study, London, United Kingdom, 17 April to 17 July 2020.","description":"IntroductionImmunoassays targeting different SARS-CoV-2-specific antibodies are employed for seroprevalence studies. The degree of variability between immunoassays targeting anti-nucleocapsid (anti-NP; the majority) vs the potentially neutralising anti-spike antibodies (including anti-receptor-binding domain; anti-RBD), particularly in mild or asymptomatic disease, remains unclear.AimsWe aimed to explore variability in anti-NP and anti-RBD antibody detectability following mild symptomatic or asymptomatic SARS-CoV-2 infection and analyse antibody response for correlation with symptomatology.MethodsA multicentre prospective cross-sectional study was undertaken (April-July 2020). Paired serum samples were tested for anti-NP and anti-RBD IgG antibodies and reactivity expressed as binding ratio","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-04T08:41:29.796Z","creation":"2025-04-04T08:41:29.796Z"},"accession":"S-EPMC8796290","cross_references":{"pubmed":["35086612"],"doi":["10.2807/1560-7917.ES.2022.27.4.2002076"]}}